Marshall Wace, LLP Cabaletta Bio, Inc. Transaction History

Marshall Wace, LLP

$78.4 Billion
Q4 2024

A detailed history of Marshall Wace, LLP transactions in Cabaletta Bio, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 193,225 shares of CABA stock, worth $425,095. This represents 0.0% of its overall portfolio holdings.

Number of Shares

193,225

Previous 283,806 31.92%

Holding current value

$425,095

Previous $1.34 Million 68.26%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 13, 2025	SELL	$1.87 - $4.91 $169,386 - $444,752	-90,581 Reduced 31.92%	193,225 $425,000
Q3 2024 Nov 14, 2024	SELL	$3.94 - $8.24 $182,741 - $382,179	-46,381 Reduced 14.05%	283,806 $1.34 Million
Q2 2024 Aug 14, 2024	BUY	$7.22 - $18.82 $1.15 Million - $2.99 Million	159,000 Added 92.88%	330,187 $2.47 Million
Q1 2024 May 15, 2024	BUY	$16.79 - $25.38 $2.87 Million - $4.34 Million	171,187 New	171,187 $2.92 Million
Q2 2023 Aug 14, 2023	SELL	$7.65 - $13.95 $1.86 Million - $3.4 Million	-243,596 Reduced 73.98%	85,696 $1.11 Million
Q1 2023 May 15, 2023	BUY	$7.08 - $12.62 $1.96 Million - $3.5 Million	277,321 Added 533.61%	329,292 $2.72 Million
Q4 2022 Feb 14, 2023	BUY	$0.64 - $9.3 $33,261 - $483,330	51,971 New	51,971 $480,000
Q2 2022 Aug 15, 2022	SELL	$0.99 - $2.11 $12,590 - $26,834	-12,718 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$1.68 - $3.92 $9,700 - $22,634	5,774 Added 83.15%	12,718 $26,000
Q4 2021 Feb 14, 2022	SELL	$3.36 - $14.64 $192,228 - $837,569	-57,211 Reduced 89.18%	6,944 $26,000
Q3 2021 Nov 15, 2021	BUY	$7.0 - $12.5 $449,085 - $801,937	64,155 New	64,155 $780,000

Others Institutions Holding CABA

# of Institutions

115

Shares Held

39.6M

Call Options Held

297K

Put Options Held

98.6K

View Full List

About Cabaletta Bio, Inc.

Ticker CABA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,014,000
Market Cap $63.8M
Description
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce di...

More about CABA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.

Account

Marshall Wace, LLP Cabaletta Bio, Inc. Transaction History